Actively Recruiting
Epirubicin Interventional Chemotherapy for Sinonasal Adenoid Cystic Carcinoma (SNACC): A Prospective Study
Led by Eye & ENT Hospital of Fudan University · Updated on 2026-05-12
100
Participants Needed
1
Research Sites
203 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is for patients with locally advanced sinonasal adenoid cystic carcinoma (SNACC), a rare and challenging cancer that tends to invade nerves and the skull base. The research aims to test a new precise treatment strategy. First, all participants will receive three sessions of "interventional chemotherapy" (transarterial chemoembolization) with the drug Epirubicin, which delivers high-dose chemotherapy directly to the tumor to shrink it as much as possible. About 4-6 weeks after the third session, doctors will use MRI scans to evaluate how well the tumor responded. Based on this response, patients will follow one of two personalized treatment paths: those whose tumors did not completely disappear will undergo surgery followed by radiotherapy; those whose tumors show complete disappearance on imaging will receive precise radiotherapy alone, potentially avoiding major surgery. This is a prospective, multicenter study. The main goals are to evaluate the safety and effectiveness of this response-adapted strategy and to see if it can improve outcomes for patients with this difficult-to-treat cancer.
CONDITIONS
Official Title
Epirubicin Interventional Chemotherapy for Sinonasal Adenoid Cystic Carcinoma (SNACC): A Prospective Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 70 years
- Histologically confirmed diagnosis of sinonasal adenoid cystic carcinoma (ACC)
- Tumor stage T3 or T4 according to AJCC 8th edition; lymph node metastasis must be operable, distant metastasis must be stable
- Ability to provide at least 0.5 cm³ of fresh tumor tissue for research
- ECOG performance status score of 0 to 2
- Voluntary participation with written informed consent and ability to comply with treatment and follow-up
You will not qualify if you...
- Prior treatment with Epirubicin or any anthracycline-based chemotherapy
- Prior radiotherapy to the head and neck region
- Chemotherapy, targeted therapy, or immunotherapy within 4 weeks before enrollment
- Participation in another interventional drug clinical trial
- Inadequate liver, kidney, or bone marrow function
- Allergies to anthracyclines, Grade 2 or higher peripheral neuropathy, or uncontrolled gastrointestinal issues
- Severe uncontrolled infection or major organ dysfunction
- Pregnancy or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Eye and ENT Hospital, Fudan University
Shanghai, Xuhui Strict, China, 200031
Actively Recruiting
Research Team
Q
Quan Liu, M.D.
CONTACT
W
Wanpeng Li, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here